An auxiliary medicinal product is a medicinal product used, as specified in the protocol, to meet the needs of a clinical trial without itself being an investigational medicinal product. It may enable trial conduct, safeguard safety, or support the collection of an endpoint. The classification determines which information, labelling, sourcing, and responsibilities are required in medicinal product management. <\/p>\n
The definition is function-based: what matters is that the medicinal product is specified in the protocol and is needed for the trial, not that it is intended to test its own trial hypothesis. Examples include background therapy, a challenge agent, emergency medication, or a medicinal product used to assess an endpoint. For each auxiliary medicinal product, purpose, dose, responsibilities, storage, dispensing, and traceability must be described clearly in the protocol and the associated documents. <\/p>\n
In principle, authorised auxiliary medicinal products should be used. Cost savings alone do not justify dispensing with an authorised medicinal product. If no authorised product is available for the intended purpose, or if a product is required under special conditions, the regulatory classification must be robustly justified in advance. This category must not be used to circumvent requirements applicable to the actual investigational medicinal product. <\/p>\n
Operational planning distinguishes auxiliary medicinal products from investigational medicinal products without excluding them from quality management. Deviations in storage, expiry, prescribing, or dispensing can affect participant protection and data analysis. Depending on the function, site training, controlled procurement, documentation forms, and aligned emergency pathways are required. If the role of a medicinal product changes, it must be assessed whether this affects the protocol or the application. <\/p>\n
Even during protocol development, each medicinal product role should be reviewed in a table. This prevents a product from being described simultaneously as background therapy, comparator treatment, and investigational medicinal product without its actual function being clearly defined. Changes in supply availability or the safety profile should be assessed via the defined medicinal product and quality pathways. <\/p>\n
The investigational medicinal product is the medicinal product being tested or used as a reference, including placebo, in a clinical trial. By contrast, the auxiliary medicinal product supports protocol-compliant conduct without assuming that role. What matters is the function defined in the protocol, not merely the known product name. <\/p>\n
The comparator medicinal product is used for comparison with the investigational medicinal product. An auxiliary medicinal product is not automatically a comparator medicinal product, even if its use influences the interpretation of results. Alongside investigational medicinal product, comparator medicinal product, and placebo, it forms a separate category that should be explicitly identified in procurement and documentation. <\/p>\n
The medicinal product role should be consistent across all study documents. The protocol, pharmacy instructions, shipping documents, prescribing processes, and database terminology must make clear whether a medicinal product is being investigated, compared, or used only in a supportive capacity. Otherwise, a site may, for example, apply incorrect accountability or storage requirements or fail to adequately assess unexpected interactions. For complex treatment regimens, a matrix is helpful to capture the purpose, supply route, responsible parties, and traceability of each product. This overview also supports verification that use as an auxiliary medicinal product is covered by the protocol. Emergency medication deserves particular attention: it must be available, but must not inadvertently become part of the intervention being compared. Clear classification therefore strengthens both patient safety and the interpretability of study results. <\/p>\n
The classification should also be re-evaluated when the protocol is amended. If the purpose, dose, or data relevance of a medicinal product changes, its regulatory role may change. A documented re-assessment prevents operational processes from being based on an outdated medicinal product classification. <\/p>\n
Before site activation, these decisions should be reviewed jointly with the pharmacy, investigator, and logistics. This makes it possible to identify and correct unclear ordering routes, contradictory storage instructions, and gaps in dispensing documentation before first use. <\/p>\n
Clear assignment also facilitates the review of supplier documentation and expiry dates. It prevents operational routine from obscuring the function of a medicinal product defined in the protocol. <\/p>\n
The existing entries investigational medicinal product, comparator medicinal product, placebo, and investigational medicinal product logistics address different aspects of the same medicinal product process. The auxiliary medicinal product complements these terms as a distinct functional category; its logistics must be planned and documented in line with its role. <\/p>\n
Categorisation errors often only become apparent when sites order, store, or dispense medicinal products. Clear assignment facilitates communication with pharmacies, training, and the monitoring of expiry dates and temperature conditions. It also protects consistency between the protocol, investigator site file, informed consent materials, and medicinal product responsibilities. <\/p>\n
Full-service CROs such as Mediconomics provide support with medicinal product classification, the preparation of medicinal product manuals, and alignment with trial sites and depots. They coordinate procurement, labelling, logistics, accountability, and the documentation of deviations in accordance with the function of the auxiliary medicinal product. <\/p>\n
Can an auxiliary medicinal product be an emergency medication?<\/strong><\/p>\n Yes. If it is specified in the protocol for safe conduct and is not an investigational medicinal product, it can be classified as an auxiliary medicinal product. <\/p>\n Is an auxiliary medicinal product always authorised?<\/strong><\/p>\n In principle, authorised auxiliary medicinal products should be used. Deviating scenarios must be justified from both a regulatory and scientific perspective. <\/p>\n Why is the distinction important for the site?<\/strong><\/p>\n Among other things, it determines training, storage, procurement, documentation, and responsibilities in handling the medicinal product.<\/p>\n An auxiliary medicinal product is a medicinal product used, as specified in the protocol, to meet the needs of a clinical trial without itself being an investigational medicinal product. It may enable trial conduct, safeguard safety, or support the collection of an endpoint. The classification determines which information, labelling, sourcing, and responsibilities are required in […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[21],"class_list":["post-7809","glossary","type-glossary","status-publish","hentry","glossary-cat-clinical-operations-gcp"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/7809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/7809\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=7809"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=7809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n